Sandbox/AL: Difference between revisions
< Sandbox
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
|+ | |+ | ||
! style="background: #4479BA; color:#FFF; width: 350px;" | Disease | ! style="background: #4479BA; color:#FFF; width: 350px;" | Disease | ||
! style="background: #4479BA; color:#FFF; width: 350px;" | Description | |||
! style="background: #4479BA; color:#FFF; width: 350px;" | Clinical Findings | ! style="background: #4479BA; color:#FFF; width: 350px;" | Clinical Findings | ||
! style="background: #4479BA; color:#FFF; width: 350px;" | Diagnosis | ! style="background: #4479BA; color:#FFF; width: 350px;" | Diagnosis | ||
| Line 8: | Line 9: | ||
! style="background: #4479BA; color:#FFF; width: 350px;" | Treatment | ! style="background: #4479BA; color:#FFF; width: 350px;" | Treatment | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Pneumocystis Pneumonia | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Pneumocystis Pneumonia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Caused by the fungus ''Pneumocystis jirovecii''. | |||
*90% of cases occurred among patients with CD4+ <200 | |||
*Incidence among HIV patients: 2-3 cases per 100 person-year | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Subacute onset of progressive dyspnea, fever, nonproductive cough, and chest discomfort that worsens within days to weeks. Tachypnea, tachycardia, and diffuse dry rales are found in the physical examination. | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Clinical presentation, blood tests, or chest x-rays are not pathognomonic for PCP. | | style="padding: 5px 5px; background: #F5F5F5;" | Clinical presentation, blood tests, or chest x-rays are not pathognomonic for PCP. | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Start TMP-SMX prophylaxys when CD4+ <200 cells/µL or | | style="padding: 5px 5px; background: #F5F5F5;" | Start TMP-SMX prophylaxys when CD4+ <200 cells/µL or history of oropharyngeal candidiasis. <br> Discontinue prohylaxys when CD4+ is >200 cells/µL for >3 month. | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*TMP-SMX | |||
*<small>Administer adjunctive corticosteroids in patients with pO2 <70 mm Hg or arterial-alveolar O2 gradient >35 mm Hg</small> | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Toxoplasma gondii Encephalitis | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Toxoplasma gondii]] Encephalitis | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Revision as of 20:08, 14 October 2014
| Disease | Description | Clinical Findings | Diagnosis | Prophylaxis | Treatment |
|---|---|---|---|---|---|
| Pneumocystis Pneumonia |
|
Subacute onset of progressive dyspnea, fever, nonproductive cough, and chest discomfort that worsens within days to weeks. Tachypnea, tachycardia, and diffuse dry rales are found in the physical examination. | Clinical presentation, blood tests, or chest x-rays are not pathognomonic for PCP. | Start TMP-SMX prophylaxys when CD4+ <200 cells/µL or history of oropharyngeal candidiasis. Discontinue prohylaxys when CD4+ is >200 cells/µL for >3 month. |
|
| Toxoplasma gondii Encephalitis | |||||
| Cryptosporidiosis | |||||
| Microsporidiosis | |||||
| Mycobacterium tuberculosis | |||||
| Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents [1] | |||||